Zanidatamab With Evorpacept for Advanced HER2-Expressing Cancer

Zanidatamab With Evorpacept for Advanced HER2-Expressing Cancer
86%55%23%Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 26 • YES 45.0%Apr 27 • YES 52.7%Apr 28 • YES 33.2%Apr 29 • YES 41.9%Apr 30 • YES 41.9%May 1 • YES 41.9%May 2 • YES 41.9%May 3 • YES 41.9%May 4 • YES 41.9%May 5 • YES 41.8%May 7 • YES 75.8%May 13 • YES 75.8%
Jazz Pharmaceuticals ($JAZZ)
No stock closeNo stock close$237.5$216.1$194.7Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 27 • JAZZ $201.2Apr 28 • JAZZ $204.0Apr 29 • JAZZ $199.9Apr 30 • JAZZ $203.0May 1 • JAZZ $202.7May 4 • JAZZ $208.1May 5 • JAZZ $212.3May 6 • JAZZ $228.6May 7 • JAZZ $227.0May 8 • JAZZ $225.8May 11 • JAZZ $223.6May 12 • JAZZ $227.8May 13 • JAZZ $232.3

Will this trial show a positive result on confirmed objective response rate by RECIST 1.1?

Paper Trading
Create account to trade
ClinicalTrialModel PositionsModel ReasoningOracle
Scientific editorial illustration for HER2-Expressing Cancers

HER2-Expressing Cancers

HER2 is a growth-signal protein that can be high in several cancers, including breast and stomach cancers. Safety endpoints matter because side effects can affect daily life and whether patients can stay on treatment.

1HER2-positive breast cancer: 15% to 20%2HER2-positive gastric cancer: 15% to 20%3U.S. breast cancer burden: About 1 in 8 women